RGNXREGENXBIO Inc.
$6.68-45% 1Y
$6.68
$5.6552 weeks$15.98
Is the price fair?
What RGNX's price assumes
REGENXBIO Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 3.63× revenue.
3.63
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 8.84
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 8.84
- EV / EBIToperating margin −94%: the multiple describes the denominator
- not meaningful
- Market capitalisation66.0 million shares, counted Jul 31, 2026
- $441M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.